Nuno Figueiredo

Prof. Nuno Figueiredo

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in The Lancet
Verified
Journal Article
Open access
MVMaxime J M van der Valk
Maxime J M van der Valk
DHDenise Hilling
Denise Hilling
EBEsther Bastiaannet
Esther Bastiaannet
EKElma Meershoek-Klein Kranenbarg
Elma Meershoek-Klein Kranenbarg
GBGeerard Beets
Geerard Beets
DZDavid D E Zimmerman
David D E Zimmerman
The strategy of watch and wait (W&W) in patients with rectal cancer who achieve a complete clinical response (cCR) after neoadjuvant therapy is new and offers an opportunity for patients to avoid major resection surgery. However, evidence is based on small-to-moderate sized series from specialist centres. The International Watch & Wait Database (IWWD) aims to describe the outcome of the W&W strategy in a large-scale registry of pooled individual patient data. We report the results of a descriptive analysis after inclusion of more than 1000 patients in the registry. Participating centres entered data in the registry through an online, highly secured, and encrypted research data server. Data included baseline characteristics, neoadjuvant therapy, imaging protocols, incidence of local regrowth and distant metastasis, and survival status. All patients with rectal cancer in whom the standard of care (total mesorectal excision surgery) was omitted after neoadjuvant therapy were eligible to be included in the IWWD. For the present analysis, we only selected patients with no signs of residual tumour at reassessment (a cCR). We analysed the proportion of patients with local regrowth, proportion of patients with distant metastases, 5-year overall survival, and 5-year disease-specific survival. Between April 14, 2015, and June 30, 2017, we identified 1009 patients who received neoadjuvant treatment and were managed by W&W in the database from 47 participating institutes (15 countries). We included 880 (87%) patients with a cCR. Median follow-up time was 3·3 years (95% CI 3·1-3·6). The 2-year cumulative incidence of local regrowth was 25·2% (95% CI 22·2-28·5%), 88% of all local regrowth was diagnosed in the first 2 years, and 97% of local regrowth was located in the bowel wall. Distant metastasis were diagnosed in 71 (8%) of 880 patients. 5-year overall survival was 85% (95% CI 80·9-87·7%), and 5-year disease-specific survival was 94% (91-96%). This dataset has the largest series of patients with rectal cancer treated with a W&W approach, consisting of approximately 50% data from previous cohort series and 50% unpublished data. Local regrowth occurs mostly in the first 2 years and in the bowel wall, emphasising the importance of endoscopic surveillance to ensure the option of deferred curative surgery. Local unsalvageable disease after W&W was rare. European Registration of Cancer Care financed by European Society of Surgical Oncology, Champalimaud Foundation Lisbon, Bas Mulder Award granted by the Alpe d'Huzes Foundation and Dutch Cancer Society, and European Research Council Advanced Grant.
1

23 August 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Rita FiorRita Fior
Rita Fior
VPVanda Póvoa
Vanda Póvoa
RMRaquel V. Mendes
Raquel V. Mendes
TCTânia Carvalho
Tânia Carvalho
AGAntonio Gomes
Antonio Gomes
Miguel Godinho FerreiraMiguel Godinho Ferreira
Miguel Godinho Ferreira
Cancer is as unique as the person fighting it. With the exception of a few biomarker-driven therapies, patients go through rounds of trial-and-error approaches to find the best treatment. Using patient-derived cell lines, we show that zebrafish larvae xenotransplants constitute a fast and highly sensitive in vivo model for differential therapy response, with resolution to reveal intratumor functional cancer heterogeneity. We screened international colorectal cancer therapeutic guidelines and determined distinct functional tumor behaviors (proliferation, metastasis, and angiogenesis) and differential sensitivities to standard therapy. We observed a general higher sensitivity to FOLFIRI [5-fluorouracil(FU)+irinotecan+folinic acid] than to FOLFOX (5-FU+oxaliplatin+folinic acid), not only between isogenic tumors but also within the same tumor. We directly compared zebrafish xenografts with mouse xenografts and show that relative sensitivities obtained in zebrafish are maintained in the rodent model. Our data also illustrate how KRAS mutations can provide proliferation advantages in relation to KRASWT and how chemotherapy can unbalance this advantage, selecting for a minor clone resistant to chemotherapy. Zebrafish xenografts provide remarkable resolution to measure Cetuximab sensitivity. Finally, we demonstrate the feasibility of using primary patient samples to generate zebrafish patient-derived xenografts (zPDX) and provide proof-of-concept experiments that compare response to chemotherapy and biological therapies between patients and zPDX. Altogether, our results suggest that zebrafish larvae xenografts constitute a promising fast assay for precision medicine, bridging the gap between genotype and phenotype in an in vivo setting. Significance Despite advances in targeted cancer treatments, we still lack methods to predict how a specific cancer will respond to a given therapy. As a consequence, patients go through rounds of trial-and-error approaches based on guidelines to find the best treatment, often subjected to unnecessary toxicity. Using cell lines, we used zebrafish larvae xenografts as sensors for cancer behavior and therapy guideline screening. Our data show not only sufficient resolution to distinguish functional tumor behaviors in just 4 days but also differential sensitivity to colorectal cancer therapy. As proof-of-principle, we provide evidence for similar behavior response to therapies in patients as in zebrafish patient-derived xenografts. Altogether, our results suggest zebrafish larvae xenografts as a promising in vivo screening platform for precision medicine.

1 November 2013 in Immunity
Verified
Journal Article
Closed access
NFNuno Figueiredo
Nuno Figueiredo
ACAngelo Chora
Angelo Chora
MRMaria Helena Raquel
Maria Helena Raquel
NPNadja Pejanovic
Nadja Pejanovic
PPPedro Pereira
Pedro Pereira
LMLuis Moita
Luis Moita

1 October 2012 in Autoimmunity Reviews
Verified
Journal Article
Closed access
RCRita Cascão
Rita Cascão
BVB. Vidal
B. Vidal
MRMaria Helena Raquel
Maria Helena Raquel
ACAna Neves Costa
Ana Neves Costa
NFNuno Figueiredo
Nuno Figueiredo
LMLuis Moita
Luis Moita

1 October 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CSCarine El Sissy
Carine El Sissy
AKAmos Kirilovsky
Amos Kirilovsky
MEMarc Van Den Eynde
Marc Van Den Eynde
AMAna-Maria Mușină
Ana-Maria Mușină
MAMaria-Gabriela Anitei
Maria-Gabriela Anitei
FPFranck Pagès
Franck Pagès
Purpose: No biomarker to personalize treatment in locally advanced rectal cancer (LARC) is currently available. We assessed in LARC whether a diagnostic biopsy-adapted immunoscore (ISB) could predict response to neoadjuvant treatment (nT) and better define patients eligible to an organ preservation strategy (“Watch-and-Wait”). Experimental Design: Biopsies from two independent cohorts (n1 = 131, n2 = 118) of patients with LARC treated with nT followed by radical surgery were immunostained for CD3+ and CD8+ T cells and quantified by digital pathology to determine ISB. The expression of immune-related genes post-nT was investigated (n = 64 patients). Results were correlated with response to nT and disease-free survival (DFS). The ISB prognostic performance was further assessed in a multicentric cohort (n = 73 patients) treated by Watch-and-Wait. Results: ISB positively correlated with the degree of histologic response (P < 0.001) and gene expression levels for Th1 orientation and cytotoxic immune response, post-nT (P = 0.006). ISB high identified patients at lower risk of relapse or death compared with ISB low [HR, 0.21; 95% confidence interval (CI), 0.06–0.78; P = 0.009]. Prognostic performance of ISB for DFS was confirmed in a validation cohort. ISB was an independent parameter, more informative than pre- (P < 0.001) and post-nT (P < 0.05) imaging to predict DFS. ISB combined with imaging post-nT discriminated very good responders that could benefit from organ preservation strategy. In the “Watch-and-Wait” cohort (n = 73), no relapse was observed in patients with ISB high (23.3%). Conclusions: ISB predicts response to nT and survival in patients with LARC treated by surgery. Its usefulness in the selection of patients eligible for a Watch-and-Wait strategy is strongly suggested.

1 December 2015 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
GBGeerard Beets
Geerard Beets
NFNuno Figueiredo
Nuno Figueiredo
AHA. Habr-Gama
A. Habr-Gama
CVC.J.H. van de Velde
C.J.H. van de Velde